Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Clinical trial NCT03361748 · COMPLETED
Trial details
- NCT number
- NCT03361748
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-13
- Primary completion
- 2023-12-20
- Enrollment
- 149
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.